Influenza virus inhibiting peptides

Details Influenza virus inhibiting peptides Influenza virus inhibiting peptides

2004-11-03

2009-02-17

Campell, Bruce (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Reexamination Certificate

active

07491793

ABSTRACT:
The present invention relates to a method of preventing or inhibiting viral infection of a cell and/or fusion between the envelope of a virus and the membranes of a cell targeted by the virus (thereby preventing delivery of the viral genome into the cell cytoplasm, a step required for. viral infection). The present invention particularly relates to the families of RNA viruses, including the arenaviruses, coronaviruses, filoviruses, orthomyxoviruses, paramyxoviruses, and retroviruses, having Class I membrane fusion proteins as the fusion proteins that mediate this fusion process. The present invention provides for a method of identifying a conserved motif or domain called the fusion initiation region (FIR) in these viruses. The present invention further provides for methods of preventing infection by such viruses, by interfering with their FIR. The present invention further provides for methods of treatment and prophylaxis of diseases induced by such viruses.

REFERENCES:
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5567805 (1996-10-01), Henderson et al.
patent: 5747239 (1998-05-01), Wang et al.
patent: 6037348 (2000-03-01), Colacino et al.
patent: WO 88/08429 (1988-11-01), None
patent: WO 94/17826 (1994-08-01), None
patent: WO 01/59457 (2001-08-01), None
patent: WO 2005/010034 (2005-02-01), None
patent: WO 2005/016238 (2005-02-01), None
Atabani, et al., Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection, Journal of Virology, 1997, 71(10):7240-7245.
Samuel, et al., Participation of two fusion peptides in measles virus-induced membrane fusion: emerging similarity with other paramyxoviruses, Biochemistry, 2001, 40:1340-1349.
Kliger, et al., Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy, BMC Microbiology, 2003, 3:20.
Chan, et al., Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target, (1998).Proc. Natl. Acad. Sci. USA95, 15613-15617.
Carr, et al., A spring-loaded mechanism for the conformational change of influenza hemagglutinin, (1993).Cell73, 823-832.
Fass, et al., Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin, (1995).Current Biology5, 1377-1383.
Clegg, et al., Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products, (1991).Virus Research18, 151-164.

Affiliated with

Also associated with

Rating

Influenza virus inhibiting peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Influenza virus inhibiting peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza virus inhibiting peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4098117